A Phase II Study of Letrozole and RAD001 (Everolimus) in Patients With Advanced or Recurrent Endometrial Cancer.

Trial Profile

A Phase II Study of Letrozole and RAD001 (Everolimus) in Patients With Advanced or Recurrent Endometrial Cancer.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Feb 2017

At a glance

  • Drugs Everolimus (Primary) ; Letrozole (Primary)
  • Indications Endometrial cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Feb 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Apr 2018.
    • 18 Feb 2016 Planned primary completion date changed from 1 Apr 2016 to 1 Apr 2017, according to ClinicalTrials.gov record.
    • 18 Feb 2014 Planned End Date changed from 1 Apr 2015 to 1 Apr 2016, as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top